Navigation Links
Addrenex Pharmaceuticals Announces Licensing Agreement With Dream Pharma
Date:8/5/2009

RESEARCH TRIANGLE PARK, N.C., Aug. 5 /PRNewswire/ -- Addrenex Pharmaceuticals, a specialty pharmaceutical company dedicated to developing treatments to regulate the adrenergic system, announced today an exclusive partnership with Dream Pharma. In keeping with its long-range plan to advance the treatment of adrenergic-related conditions throughout the world, Addrenex has licensed the right to manufacture, market and sell its lead product, Clonicel, in Korea to Dream Pharma. Dream Pharma is a Division of the Hanwha Group, one of the top 10 business conglomerates in Korea.

Clonicel is being developed for both the treatment of hypertension and attention deficit hyperactivity disorder. Clonicel is a patented extended-release formulation of clonidine hydrochloride, a drug currently approved for hypertension.

"We are very excited to partner with Dream Pharma to bring this important treatment to children struggling with ADHD in Korea," said Steve Butts, Vice President, Commercial Operations at Addrenex Pharmaceuticals. "This agreement is another important milestone for Addrenex as we continue to expand our business activities globally."

This partnership agreement coincides with the 3rd anniversary of the founding of Addrenex. In just three short years, the company has signed several licensing deals with major pharmaceutical companies, advanced four products to various stages of clinical trials and acquired an extensive pipeline of compounds primed for future development. Moving forward, the company will continue to focus on developing treatments for the origin of a wide range of conditions regulated by the adrenergic system. These conditions range from menopausal flushing to insomnia to pain. Currently, these conditions are being managed symptomatically rather than addressing the root cause.

"It is exciting to see so much progress in such a short period of time. We have grown from a company with a single product to one with a strong portfolio of products, have already filed our first NDA and are preparing to file a second. We have also entered into several global partnerships," said Moise Khayrallah, Ph.D., cofounder and CEO of Addrenex. "We know this partnership with Dream Pharma will serve to contribute to our ongoing growth and success while benefiting a great number of patients."

About Addrenex Pharmaceuticals, Inc.

Addrenex Pharmaceuticals is a focused, specialty pharmaceutical company that develops and commercializes drugs to treat adrenergic dysregulation. Addrenex Pharmaceuticals is based in Durham, N.C., on the edge of Research Triangle Park. The company's mission is to explore the impact that neurotransmitter regulation has on a variety of diseases and disorders. Addrenex identified adrenergic regulation as its initial research focus. Adrenergic dysregulation is implicated in medical conditions such as hypertension, ADHD, migraine and post-menopausal symptoms.

In addition to its partnered programs, Clonicel (hypertension and ADHD) and ADX-415 (hypertension and menopausal flushing), Addrenex has two proprietary products in clinical development, ADX-N05 for the treatment of narcolepsy and ADX-117 for procedural sedation. For more information, visit www.addrenex.com


'/>"/>
SOURCE Addrenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... OH (PRWEB) , ... February 19, 2017 , ... Braun ... The JEMS Conference & Exposition, the event will take place February 23-25, 2017 at ... Industries will be in Booth #909 with three new ambulances on display. ...
(Date:2/19/2017)... ... February 19, 2017 , ... ... home healthcare, will join forces with Healthwise ® at HIMSS 2017 ... the industry leader in evidence-based health education, technology and services, will demonstrate a ...
(Date:2/18/2017)... ... ... Butler Mobility invited Ken Matthews to visit its manufacturing facility and showroom ... impressed with the safety and reliability of the Stannah Stairlift as well as with ... endorsement by Ken Matthews can be heard on News Radio WHP 580 weekdays from ...
(Date:2/18/2017)... ... February 18, 2017 , ... ProParagraph Fashion Volume 2 ... ’ ProParagraph Fashion Volume 2 for all multi-line FCPX project needs. Great ... pick and choose from hand-crafted trend-setting designs with smooth animations that will add ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... kept pace. Enovate Medical has introduced an innovative workstation designed to reduce nursing ... nurses, the Encore Mobile EHR Workstation offers a lightweight, highly mobile, multi-functional alternative ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... According to a new market research report "Particle Counters Market ... Contamination Monitoring of Liquids), and End User (Healthcare Industry, Semiconductor Industry) ... expected to reach USD 330.6 Million by 2021 from USD 275.9 ... 2021. Continue Reading ... ...
(Date:2/17/2017)... , Feb. 17, 2017 Theravance ... Biopharma" or the "Company") today announced the presentation ... potent, and orally administered pan-Janus kinase (JAK) inhibitor ... th Congress of the European Crohn,s and ... Company reported further data from its completed Phase ...
(Date:2/17/2017)... -- Research and Markets has announced the addition of the ... their offering. ... separate comprehensive analytics for the US, Canada , ... , and Rest of World. Annual estimates and forecasts are provided ... provided for these markets. Market data and analytics are derived from primary ...
Breaking Medicine Technology: